Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.
1 report, 1 independent
Updated Sep 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald and Wells Fargo raised price targets for Regeneron Pharmaceuticals stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
-
Cantor Fitzgerald
American financial services company
-
Wells Fargo
American multinational banking and financial services company
Related events
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald raised its price target on Salesforce on September 1, 2026.
- Morgan Stanley and Cantor Fitzgerald raised target prices, while filings detailing stock changes were submitted to the SEC.
- Cantor Fitzgerald raised its price target and rating, while Bank of America adjusted its rating and price target, with MarketBeat aggregating the stock rating data.
- Cantor Fitzgerald raised its price target on Texas Instruments shares on July 8, 2026.